hydroxyurea has been researched along with Hemoglobinopathies in 32 studies
Hemoglobinopathies: A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The klf10 gene could indirectly modify γ-globin chain production and hence the level of fetal hemoglobin (HbF) ameliorating the phenotype of β-hemoglobinopathies and the response to hydroxycarbamide (hydroxyurea [HU]) therapy." | 7.85 | Klf10 Gene, a Secondary Modifier and a Pharmacogenomic Biomarker of Hydroxyurea Treatment Among Patients With Hemoglobinopathies. ( Aly, NH; El Sherif, NH; Elalfy, MS; Kamal, TM, 2017) |
| "Hydroxyurea is known to reduce ineffective erythropoiesis and thereby hemolysis leading to a reduction in bilirubin levels in patients with hemoglobinopathies." | 7.76 | The effect of UGT1A1 promoter polymorphism on bilirubin response to hydroxyurea therapy in hemoglobinopathies. ( Colah, RB; Ghosh, K; Italia, KY; Jain, D; Jijina, FF; Merchant, R; Mukherjee, M; Nadkarni, AH, 2010) |
| " Hydroxyurea, EPO preparations, sodium phenylbutyrate, arginine butyrate, and 5-azacytidine/decitabine have shown efficacy in approximately 40% to 70% of sickle cell and beta-thalassemia patients." | 4.84 | Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. ( Perrine, SP, 2008) |
| " Single nucleotide polymorphisms (SNPs) in genes located within as well as outside the human beta-globin cluster have recently been shown to be significantly associated with Hb F increase in relation to hydroxyurea (HU) treatment in hemoglobinopathies patients." | 4.84 | Pharmacogenomics and therapeutics of hemoglobinopathies. ( Grosveld, FG; Patrinos, GP, 2008) |
| "Hydroxyurea is an S-phase-specific drug that reversibly inhibits ribonucleoside diphosphate reductase enzyme which catalyses an essential step in the DNA biosynthesis." | 2.72 | A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic. ( Mettananda, S; Premawardhena, A; Yasara, N, 2021) |
| " However, application of these drugs at large is not yet justified because a series of questions concerning their long-term efficacy, the correct dosage and timing, their tolerance and toxicity, and the potential long-term dangers, including mutagenicity are still unresolved." | 2.40 | New therapies for the haemoglobinopathies. ( Loukopoulos, D, 1997) |
| "Both diagnosis and treatment of hemoglobinopathies have been associated with an increased risk of fertility impairment." | 1.91 | Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies. ( Balcerek, M; Borgmann-Staudt, A; Diepold, M; Diesch-Furlanetto, T; Drexler, B; Dülberg, J; Eisenreich, B; Friedrich, LA; Hegemann, I; Infanti, L; Kager, L; Kroiss, S; Mandic, L; Merki, R; Njue, LM; Radauer-Plank, AC; Roll, S; Rovó, A; Salow, V; Scheinemann, K; Schilling, R; Schneider, M; Sommerhäuser, G, 2023) |
| "Moreover, genotype analysis of β-thalassemia major and intermedia patients and an independent cohort of β-thalassemia/SCD compound heterozygous patients that do or do not respond to HU treatment showed that the homozygous mutant state of a tagSNP in the KLF10 3'UTR is not present in β-thalassemia intermedia patients and is underrepresented in β-thalassemia/SCD compound heterozygous patients that respond well to HU treatment." | 1.38 | KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. ( Bartsakoulia, M; Borg, J; Christou, S; Felice, AE; Georgitsi, M; Grosveld, FG; Hou, J; Karkabouna, S; Kleanthous, M; Kourakli, A; Lappa-Manakou, C; Lederer, C; Ozgur, Z; Papachatzopoulou, A; Patrinos, GP; Philipsen, S; Phylactides, M; Stavrou, EF; Tafrali, C; van Ijcken, W; von Lindern, M, 2012) |
| "Based on the molecular analysis of beta-thalassemia intermedia, beta-thalassemia homozygotes or compound heterozygotes combined with alpha-thalassemia, as well as the conjunctive abnormalities of beta-thalassemia heterozygote with triplicated haplotype of alpha-globin genes, were the most common cause of thalassemia intermedia in China." | 1.31 | The studies of hemoglobinopathies and thalassemia in China--the experiences in Shanghai Institute of Medical Genetics. ( Huang, S; Zeng, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.38) | 18.7374 |
| 1990's | 9 (28.13) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 8 (25.00) | 24.3611 |
| 2020's | 5 (15.63) | 2.80 |
| Authors | Studies |
|---|---|
| Patrinos, GP | 3 |
| Chui, DHK | 1 |
| Hardison, RC | 1 |
| Steinberg, MH | 1 |
| Starlard-Davenport, A | 1 |
| Gu, Q | 1 |
| Pace, BS | 1 |
| Radauer-Plank, AC | 1 |
| Diesch-Furlanetto, T | 1 |
| Schneider, M | 1 |
| Sommerhäuser, G | 1 |
| Friedrich, LA | 1 |
| Salow, V | 1 |
| Dülberg, J | 1 |
| Diepold, M | 1 |
| Rovó, A | 1 |
| Njue, LM | 1 |
| Drexler, B | 1 |
| Infanti, L | 1 |
| Kroiss, S | 1 |
| Merki, R | 1 |
| Scheinemann, K | 1 |
| Eisenreich, B | 1 |
| Hegemann, I | 1 |
| Mandic, L | 1 |
| Kager, L | 1 |
| Borgmann-Staudt, A | 1 |
| Schilling, R | 1 |
| Roll, S | 1 |
| Balcerek, M | 1 |
| Tauseef, U | 1 |
| Anjum, M | 1 |
| Ibrahim, M | 1 |
| Baqai, HS | 1 |
| Tauseef, A | 1 |
| Tauseef, M | 1 |
| Asghar, MS | 1 |
| Zafar, M | 1 |
| Rasheed, U | 1 |
| Shaikh, N | 1 |
| Yasara, N | 1 |
| Premawardhena, A | 1 |
| Mettananda, S | 1 |
| Hankins, JS | 1 |
| Estepp, JH | 1 |
| Hodges, JR | 1 |
| Villavicencio, MA | 1 |
| Robison, LL | 1 |
| Weiss, MJ | 1 |
| Kang, G | 1 |
| Schreiber, JE | 1 |
| Porter, JS | 1 |
| Kaste, SC | 1 |
| Saving, KL | 1 |
| Bryant, PC | 1 |
| Deyo, JE | 1 |
| Nottage, KA | 1 |
| King, AA | 1 |
| Brandow, AM | 1 |
| Lebensburger, JD | 1 |
| Adesina, O | 1 |
| Chou, ST | 1 |
| Zemel, BS | 1 |
| Smeltzer, MP | 1 |
| Wang, WC | 1 |
| Gurney, JG | 1 |
| Boucher, AA | 1 |
| Gurunathan, A | 1 |
| Taylor, JM | 1 |
| Ricci, KW | 1 |
| Vadivelu, S | 1 |
| Quinn, CT | 1 |
| Russo, G | 2 |
| De Franceschi, L | 1 |
| Colombatti, R | 1 |
| Rigano, P | 2 |
| Perrotta, S | 1 |
| Voi, V | 1 |
| Palazzi, G | 1 |
| Fidone, C | 1 |
| Quota, A | 1 |
| Graziadei, G | 1 |
| Pietrangelo, A | 1 |
| Pinto, V | 1 |
| Ruffo, GB | 1 |
| Sorrentino, F | 1 |
| Venturelli, D | 1 |
| Casale, M | 1 |
| Ferrara, F | 1 |
| Sainati, L | 1 |
| Cappellini, MD | 1 |
| Piga, A | 1 |
| Maggio, A | 2 |
| Forni, GL | 1 |
| Allali, S | 1 |
| Taylor, M | 1 |
| Albinni, S | 1 |
| Amiranoff, D | 1 |
| de Montalembert, M | 1 |
| Oberoi, S | 1 |
| Das, R | 1 |
| Trehan, A | 1 |
| Ahluwalia, J | 1 |
| Bansal, D | 1 |
| Malhotra, P | 1 |
| Marwaha, RK | 1 |
| Elalfy, MS | 1 |
| El Sherif, NH | 1 |
| Kamal, TM | 1 |
| Aly, NH | 1 |
| Perrine, SP | 1 |
| Mabaera, R | 1 |
| West, RJ | 1 |
| Conine, SJ | 1 |
| Macari, ER | 1 |
| Boyd, CD | 1 |
| Engman, CA | 1 |
| Lowrey, CH | 1 |
| Italia, KY | 1 |
| Jijina, FF | 1 |
| Jain, D | 1 |
| Merchant, R | 1 |
| Nadkarni, AH | 1 |
| Mukherjee, M | 1 |
| Ghosh, K | 1 |
| Colah, RB | 1 |
| Borg, J | 1 |
| Phylactides, M | 1 |
| Bartsakoulia, M | 1 |
| Tafrali, C | 1 |
| Lederer, C | 1 |
| Felice, AE | 1 |
| Papachatzopoulou, A | 1 |
| Kourakli, A | 1 |
| Stavrou, EF | 1 |
| Christou, S | 1 |
| Hou, J | 1 |
| Karkabouna, S | 1 |
| Lappa-Manakou, C | 1 |
| Ozgur, Z | 1 |
| van Ijcken, W | 1 |
| von Lindern, M | 1 |
| Grosveld, FG | 2 |
| Georgitsi, M | 1 |
| Kleanthous, M | 1 |
| Philipsen, S | 1 |
| La Spina, M | 1 |
| Atweh, GF | 1 |
| DeSimone, J | 1 |
| Saunthararajah, Y | 1 |
| Fathallah, H | 1 |
| Weinberg, RS | 1 |
| Nagel, RL | 1 |
| Fabry, ME | 1 |
| Adams, RJ | 1 |
| D'Amico, G | 1 |
| Mascolino, A | 1 |
| Bachir, D | 1 |
| Galacteros, F | 2 |
| Rodgers, GP | 1 |
| Rachmilewitz, EA | 1 |
| Rose, C | 1 |
| Bauters, F | 1 |
| Olivieri, NF | 1 |
| Loukopoulos, D | 1 |
| Hattori, Y | 1 |
| Zeng, Y | 1 |
| Huang, S | 1 |
| Stamatoyannopoulos, JA | 1 |
| Nienhuis, AW | 1 |
| Marwick, C | 1 |
| Nathan, DG | 3 |
| Dean, A | 1 |
| Wu, YJ | 1 |
| Ley, T | 1 |
| Fordis, CM | 1 |
| Schechter, AN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia[NCT05469828] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2024-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for hydroxyurea and Hemoglobinopathies
| Article | Year |
|---|---|
Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Gene Expression; Hemoglobinopathies; Humans; Hydroxyurea; Mic | 2022 |
A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.
Topics: Bloodless Medical and Surgical Procedures; COVID-19 Drug Treatment; Enzyme Inhibitors; Hemoglobinopa | 2021 |
Current challenges in the management of patients with sickle cell disease - A report of the Italian experience.
Topics: Anemia, Sickle Cell; Disease Management; Hematologic Diseases; Hemoglobinopathies; Humans; Hydroxyur | 2019 |
Transfusing children with hemoglobinopathies.
Topics: Allografts; Anemia, Sickle Cell; Child; Emergencies; Erythrocyte Transfusion; Exchange Transfusion, | 2019 |
Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythropoiesis; Erythropoietin; Fatty Ac | 2008 |
A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger.
Topics: Adolescent; Animals; Butyrates; Clinical Trials as Topic; DNA (Cytosine-5-)-Methyltransferases; Drug | 2008 |
New drugs for childhood anemia.
Topics: Adult; Age Factors; Anemia; Anemia, Hemolytic, Autoimmune; Anemia, Sickle Cell; Antibodies, Monoclon | 2003 |
Hemoglobinopathies.
Topics: Animals; Azacitidine; Butyrates; Cerebral Hemorrhage; Decitabine; Disease Models, Animal; DNA Methyl | 2003 |
Pharmacogenomics and therapeutics of hemoglobinopathies.
Topics: Azacitidine; Butyrates; Decitabine; Fetal Hemoglobin; Genome, Human; Hemoglobinopathies; Humans; Hyd | 2008 |
[Potential alternatives to erythrocyte transfusion in hemoglobinopathies: hydroxyurea (HU), erythropoietin (EPO), butyrate derivatives, blood substitutes].
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Substitutes; Butyrates; Child; Erythrocyte Transfusion | 1994 |
Novel treatment options in the severe beta-globin disorders.
Topics: Erythropoietin; Fatty Acids, Volatile; Genetic Therapy; Globins; Hemoglobinopathies; Humans; Hydroxy | 1995 |
Fetal erythropoiesis and the diagnosis and treatment of hemoglobin disorders in the fetus and child.
Topics: alpha-Thalassemia; Antisickling Agents; Erythropoiesis; Fetal Diseases; Fetus; Globins; Hemoglobinop | 1997 |
New therapies for the haemoglobinopathies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Butyrates; Butyric Acid; Drug Therapy, Combination; Erythr | 1997 |
[Diagnosis and therapy of hemoglobinopathies].
Topics: Antisickling Agents; Bone Marrow Transplantation; Globins; Hemoglobinopathies; Humans; Hydroxyurea; | 1999 |
Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythropoietin; Fetal Hemoglobin; Gene Expression Regulat | 1992 |
Pharmacologic manipulation of fetal hemoglobin in the hemoglobinopathies.
Topics: Animals; Erythrocytes; Fetal Hemoglobin; Gene Expression; Hemoglobin A; Hemoglobinopathies; Humans; | 1990 |
Augmentation of hemoglobin synthesis by S-phase specific drugs in the K562 cell line.
Topics: Adult; Azacitidine; Cell Line; Cytarabine; Deoxyribonuclease HpaII; DNA Restriction Enzymes; Fetal H | 1985 |
Regulation of fetal hemoglobin synthesis by cell cycle specific drugs.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Animals; Cell Cycle; Colony-Forming Units Assay; DNA; DNA (C | 1985 |
14 other studies available for hydroxyurea and Hemoglobinopathies
| Article | Year |
|---|---|
Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Hemoglobinopathies; Humans; Hydroxyurea; Pharmacogenetics | 2021 |
Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Counseling; Cross-Sectional Studies; Female; Fertilit | 2023 |
OCCURRENCE OF UNUSUAL HAEMOGLOBINOPATHIES IN BALOCHISTAN: HB SD AND HB SE - PRESENTATION WITH OSTEOMYELITIS.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Sickle Cell; Anti-Bacterial Agents; Antis | 2021 |
Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biological Specimen Banks; Blood Transfusion; Body Fluids; C | 2018 |
Hemoglobin Southampton complicated by cerebral ischemia, moyamoya, and hydroxyurea-induced methemoglobinemia.
Topics: Aspirin; Brain Ischemia; Child; Female; Hemoglobinopathies; Hemoglobins, Abnormal; Humans; Hydroxyur | 2019 |
HbSD-Punjab: clinical and hematological profile of a rare hemoglobinopathy.
Topics: Acute Chest Syndrome; Anemia; Antisickling Agents; Child; Child, Preschool; Chromatography, High Pre | 2014 |
Klf10 Gene, a Secondary Modifier and a Pharmacogenomic Biomarker of Hydroxyurea Treatment Among Patients With Hemoglobinopathies.
Topics: Child; Cross-Sectional Studies; Early Growth Response Transcription Factors; Fetal Hemoglobin; Genes | 2017 |
The effect of UGT1A1 promoter polymorphism on bilirubin response to hydroxyurea therapy in hemoglobinopathies.
Topics: Adolescent; Adult; Bilirubin; Child; Gene Deletion; Glucuronosyltransferase; Hemoglobinopathies; Hum | 2010 |
KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Topics: 3' Untranslated Regions; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Early Gr | 2012 |
Treatment with hydroxyurea and iron chelation therapy in patients with hemoglobinopathies.
Topics: Ferritins; Hemoglobinopathies; Humans; Hydroxyurea; Iron Chelating Agents | 2005 |
Hydroxyurea therapy in highly unstable hemoglobin carriers.
Topics: Adult; Anemia, Hemolytic; Combined Modality Therapy; Female; Fetal Hemoglobin; Gene Expression Regul | 1996 |
The studies of hemoglobinopathies and thalassemia in China--the experiences in Shanghai Institute of Medical Genetics.
Topics: beta-Thalassemia; China; Globins; Hemoglobinopathies; Heterozygote; Homozygote; Humans; Hydroxyurea; | 2001 |
Sickle cell problems continue to challenge medical science, but some progress is noted.
Topics: Anemia, Sickle Cell; Female; Fetal Hemoglobin; Hemoglobinopathies; Humans; Hydroxyurea; Sickle Cell | 1990 |
Regulation of fetal hemoglobin synthesis in the hemoglobinopathies.
Topics: Anemia, Sickle Cell; Animals; Cells, Cultured; Erythropoiesis; Fetal Hemoglobin; Haplorhini; Hematop | 1985 |